Document is current

Any future updates will be listed below

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Crossref DOI link: https://doi.org/10.1007/s10549-014-3010-y

Published Online: 2014-06-19

Published Print: 2014-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark